Connect with us


Parthenon Therapeutics Showcases New Precision Oncology Technology Designed to Breakdown Barriers in Immune-excluded Tumors




BOSTON–(BUSINESS WIRE)–Parthenon Therapeutics, a precision oncology company inventing a new class of cancer therapies that reprogram the tumor microenvironment (TME), today unveiled its precision medicine approach to treating cancers with unmet need, during of the Stifel Healthcare conference.

“We are excited to showcase our pipeline and technology to the scientific community and anticipate that we will pioneer a new approach to treating patients with immune-excluded tumors. Specifically, immune exclusivity describes a distinct category of TME where a patient’s T cells are unable to attack a tumor due to the formation of a barrier around the tumor cells. Our data showed that more than 50% of solid tumors are immuno-excluded, indicating a significant unmet need for these patients,” said Laurent Audoly, co-founder and CEO of Parthenon Therapeutics. “We also presented our main asset, PRTH-101, which targets DDR1 (Discoidin Domain Receptor 1) to open the mechanical barrier that characterizes immuno-excluded tumors, and thus make tumors vulnerable to treatment. We are excited to develop one of the first therapeutic and patient selection strategies to treat this class of tumors, and expect to provide more details in the coming months. Notably, the second half of 2023 will be a catalyst as we launch our first-in-human clinical study in a well-defined patient population.

About Parthenon Therapeutics

Parthenon Therapeutics invents a new class of cancer therapies that reprogram the tumor microenvironment (TME). The interaction between cancer cells and their surrounding microenvironment is relevant in drug development, as many cancers use TME to build barriers that protect against attacks by the immune system. One approach, PRTH-101, breaks down these barriers to defeat stubborn cancers. Based on rigorous and groundbreaking research, we are designing a portfolio of drug candidates to treat the right patients at the right time. For more information, visit and LinkedIn.